BriaCell signs manufacturing deal with FUJIFILM Biotechnologies for Bria-IMT Phase 3 supply
BCTX•Manufacturing deal secures Phase 3 supply
- Briacell Therapeutics signed a manufacturing arrangement with FUJIFILM Biotechnologies California to supply Bria-IMT for its pivotal Phase 3 study.
- The deal secures capacity for the remainder of the Phase 3 program, targeting commercial-scale manufacturing if Bria-IMT advances.
- Bria-IMT is being tested with an immune checkpoint inhibitor in metastatic breast cancer.
